News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 22, 2024

Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

Author(s)Robert O'Brien, RPh, Diana I. Brixner, PhD, RPh, Ashley Peterson, MHA

Medical experts identify key stakeholders within health plans who collaborate in the decision-making process for coverage, access, and benefit design related to prescription digital therapeutics.

Episodes in this series

Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"

EP. 1 Differentiating PDTs from Wellness Apps and Evaluating Efficacy

Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"

EP. 2 Payer Needs and Strategies for Evaluating and Covering PDTs

A panel of 4 experts on PDTs

EP. 3 Payers Review Process and Effective Strategies for PDT Coverage

A panel of 4 experts on PDTs

EP. 4 Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

Video 5 - "Dawn of the Age of Adopting PDTs"

EP. 5 Dawn of the Age of Adopting PDTs

Video 6 -"Identifying the Most Impactful Disease Areas and Patient Populations for PDTs"

EP. 6 Identifying the Most Impactful Disease Areas and Patient Populations for PDTs

4 KOLs discuss PDTs

EP. 7 Evolving Commercialization and Distribution Models for PDTs

4 KOLs discuss PDTs

EP. 8 Promoting Appropriate PDT Prescribing Through Provider Education and Support

A panel of 4 experts on PDTs

EP. 9 Optimizing Provider Education, Utilization Monitoring, and Value-Based Contracts for PDTs

A panel of 4 experts on PDTs

EP. 10 Optimizing Benefit Design and Implementation for Improved PDT Access

A panel of 4 experts on PDTs

EP. 11 PDTs' Role in Addressing Health Care Disparities and Priorities for Improving PDT Access

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Car exhaust | Image Credit: olando - stock.adobe.com

FITs Offer Lowest Environmental Footprint Among CRC Screening Options

ByBrooke McCormick

August 17th 2026

COVID | Image credit: phonlamaiphoto - stock.adobe.com

COVID Is Back in the Bay Area: Is It the XFG "Stratus" Variant?

BySabrina McCrear

August 17th 2026

Zanubrutinib | Image Credit: © luchschenF-stock.adobe.com

Zanubrutinib Outlasting Acalabrutinib in CLL

ByMaggie L. Shaw

August 17th 2026

Helen Nde, MPH

Hepatitis B Re-Engagement Efforts Underreported in Lower-Resource Settings: Helen Nde, MPH

ByBrooke McCormick,Helen Nde, MPH,Laura Joszt, MA

August 17th 2026

Brittany G. Craiglow, MD, FAAD in part 3 of an AJMC interview

Closing Evidence Gaps in Managed Care for Pediatric Alopecia Areata: A Q&A With Brittany Craiglow, MD

BySkylar Jeremias,Brittany G. Craiglow, MD, FAAD

August 17th 2026

Trending on AJMC

COVID Is Back in the Bay Area: Is It the XFG "Stratus" Variant?

ICER Draft Flags High Cost of New Hypertension Drug Class

Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care

FDA Clears Lerodalcibep-Liga Autoinjector, Widens LDL-C Indication

What Comes After Anti-VEGF in Wet AMD: Arshad Khanani, MD